Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Ensituximab Shows Promise in Refractory mCRC

April 8th 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.

Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC

April 5th 2016

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

Potential Biomarkers in Metastatic Colorectal Cancer

February 26th 2016

PI3K-Mutant Metastatic Colorectal Cancer

February 26th 2016

Microsatellite Instability Status in Colorectal Cancer

February 26th 2016

BRAF Testing in Colorectal Cancer

February 26th 2016

Pathways of Resistance in Metastatic Colorectal Cancer

February 26th 2016

Upfront EGFR Therapy in Metastatic Colorectal Cancer

February 26th 2016

EGFR Therapy as Upfront Colorectal Cancer Treatment

February 26th 2016

The Current Status of RAS Testing in Colorectal Cancer

February 26th 2016

Colorectal Cancer: Challenges in Next-Generation Sequencing

February 26th 2016

Practical Considerations in Molecular Testing in CRC

February 26th 2016

Prognostic and Predictive Markers in Colorectal Cancer

February 26th 2016

Salvage Therapy and Emerging Agents in Colorectal Cancer

February 25th 2016

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.

Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

February 24th 2016

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Genomic Complexity Stifles Targeted Advances in Colorectal Cancer

February 16th 2016

Experts in the field assert that the path forward requires a paradigm shift toward integrative analyses that encompass multiple classes of genomic aberrations and consensus classification of CRC based on genomic data to facilitate more effective management of this disease.

Sequencing Decisions in Relapsed/Refractory Colorectal Cancer

February 12th 2016

The Role of TAS-102 in Metastatic Colorectal Cancer

February 12th 2016